Fairchild et al. - 2012 - Quality assurance in the EORTC 22033–26033CE5 phase III randomized trial for low grade glioma The digital individual case review - Radiother Oncol.pdf
Fairchild, A.; EORTC Headquarters, Brussels, Belgium, Radiation Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada
Weber, D. C.; Radiation Oncology, Geneva University Hospital, Switzerland
Bar-Deroma, R.; Oncology Department, Rambam Medical Centre, Haifa, Israel
GULYBAN, Akos ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
Fenton, P. A.; EORTC Headquarters, Brussels, Belgium, University Hospital Southampton, United Kingdom
Stupp, R.; Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland
Baumert, B. G.; Department of Radiation Oncology (MAASTRO), GROW (School for Oncology and Developmental Biology), Maastricht University Medical Centre (MUMC), Netherlands
Language :
English
Title :
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: The digital individual case review
F. Pignatti, M. van den Bent, and D. Curran Prognostic factors for survival in adult patients with cerebral low grade glioma J Clin Oncol 20 2002 2076 2084
M. van den Bent, D. Afra, and O. de Witte EORTC Radiotherapy and Brain Tumour Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial Lancet 366 2005 985 990
P. Brown, J. Buckner, J. Uhm, and E. Shaw The neurocognitive effects of radiation in adult low-grade glioma patients Neurooncology 5 2003 161 167
M. Klein, J. Heimans, and N. Aaronson Effect of radiotherapy and other treatment related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study Lancet 360 2002 1361 1368
E.G. Shaw, R. Arusell, and B. Scheithauer A prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a NCCTG-RTOG-ECOG study J Clin Oncol 20 2002 2267 2276
O. Surma-Aho, M. Niemelä, and J. Vilkki Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients Neurology 56 2001 1285 1290
N. Pouratian, J. Gasco, J. Sherman, M. Shaffrey, and D. Schiff Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas J Neurooncol 82 2007 281 288
K. Hoang-Xuan, L. Capelle, and M. Kujas Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions J Clin Oncol 22 2004 3133 3138
M. Brada, L. Viviers, and C. Abson Phase II study of primary temozolamide chemotherapy in patients with WHO grade II gliomas Ann Oncol 14 2003 1715 1721
J. Quinn, D. Reardon, and A. Friedman Phase II trial of temozolomide in patients with progressive low-grade glioma J Clin Oncol 21 2003 646 651
V. Kouloulias, J.-F. Bosset, and G. van Tienhoven Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer: evaluation of the individual case review procedure Eur J Cancer 38 2002 1849 1856
A. Glicksman, L. Reinstein, R. Brotman, and D. McShan Quality assurance programs in clinical trials Can Treat Rep 64 1980 425 433
T. Budiharto, E. Musat, and P. Poortmans Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group in the 21st century Radiother Oncol 88 2008 403 410
M. Pettersen, E. Aird, and D. Olsen Quality assurance of dosimetry and the impact on sample size in randomized clinical trials Radiother Oncol 86 2008 195 199
J. Horiot, J. Bernier, K. Johansson, E. van der Schueren, and H. Bartelink Minimum requirements for quality assurance in radiotherapy Radiother Oncol 29 1993 103 104
M. Bolla, H. Bartelink, and G. Garavaglia EORTC guidelines for writing protocols for clinical trials of radiotherapy Radiother Oncol 36 1995 1 8
O. Matzinger, P. Poortmans, and J.Y. Giraud Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review Radiother Oncol 90 2009 285 290
B. Baumert, M. Brada, and J. Bernier EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm Radiother Oncol 88 2008 163 172
D. Weber, P. Poortmans, and C. Hurkmans Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicentre international setting Radiother Oncol 100 2011 150 156
E. Musat, E. Roelofs, and R. Bar-Deroma Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: first evaluation of quality of radiotherapy planning Radiother Oncol 95 2010 218 224
P. Poortmans, F. Ataman, and J.B. Davis Quality assurance in the EORTC phase III randomised 'boost vs no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period Radiother Oncol 76 2005 278 284